The Bio Report is a weekly podcast hosted by award-winning journalist, Daniel Levine. Produced by the Levine Media Group, the well-respected podcast focuses on the intersection of disease with business, science, and policy, and features interviews with leaders in pharmaceuticals, biotech, and health.

Professor Catharina Svanborg, Chairman of Hamlet BioPharma, is interviewed as their title speaker in this week’s episode. The podcast discusses non–muscle invasive bladder cancer, Hamlet BioPharma’s new class of therapies, Hamlet’s clinical trials, future innovation, expansion into the US and new international partnerships, including the new trials at the University of Iowa, as one example.

Key questions included: there are many companies working in oncology and infectious disease. What is unique about Hamlet’s approach that sets it apart from more traditional drug developers? And Hamlet is developing therapies that draw on human biology, rather than relying on traditional chemotherapies or antibiotics. How does that philosophy influence how Hamlet BioPharma designs drugs and chooses which problems to tackle?

The in-depth feature interview and podcast is available on iTunes and other platforms now.

Daniel S. Levine is a journalist at Levine Media Group, RARECast, Rare Daily, and The Bio Report, specializing in life sciences. To listen to the podcast, visit: https://thebioreport.podbean.com/e/enabling-patient-foundations-to-build-the-next-generation-of-genetic-therapies/

For further information, please contact

Jakob Testad, CEO, Hamlet BioPharma AB, +46 708 48 42 10,

jakob.testad@hamletbiopharma.com

Catharina Svanborg, Chairman, Hamlet BioPharma AB, +46 709 42 65 49,

catharina.svanborg@hamletpharma.com